Protein p16INK4A expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of uterine cervix

Indian Journal of Pathology and Microbiology

Volumn 53, Issue 1, 2010, Pages 7-11

  Gupta, Ruchi ^a   Srinivasan, Radhika ^a   Nijhawan, Raje ^a   Suri, Vanita ^a   Uppal, Radha ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Cervical intraepithelial neoplasia; P16; Squamous cell carcinoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; CANCER GRADING; CANCER INVASION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; FEMALE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; POST HOC ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX EPITHELIUM;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIA; MICROSCOPY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; UTERINE NEOPLASMS;

EID: 77749333026     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.59174     Document Type: Article

References (35)

1. Stoler MH. Human papillomavirus biology and cervical neoplasia: implications for diagnostic criteria and testing. Arch Pathol Lab Med 2003;127:935-9.
2. Ferlay J, Bray F, Pisani P, DM. P. GLOBOCAN 2002 cancer incidence. Mortality and prevalence worldwide. In: IARC Cancer Base: Lyon IARC Press Cancer Base No. 5 version 2.0;2004.
3. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71.
4. Winer RL, Kiviat NB, Hughes J P, Adam DE, Lee SK, Kuypers JM, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-8.
5. Castle PE, Ashfaq R, Ansari F, Muller C Y. Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix. Cancer Lett 2005;229:245-52.
6. Tam S W, Shay JW, Pagano M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res 1994;54:5816-20.
7. Münger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002;89:213-28.
8. Tringler B, Gup CJ, Singh M, Groshong S, Shroyer AL, Heinz DE, et al. Evaluation of p16INK4a and pRb expression in cervical squamous and glandular neoplasia. Hum Pathol 2004;35:689-96.
9. Masumoto N, Fujii T, Ishikawa M, Saito M, Iwata T, Fukuchi T, et al. P16 overexpression and human papillomavirus infection in small cell carcinoma of the uterine cervix. Hum Pathol 2003;34:778-83.
10. (INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84.
11. INK4a is a non-rare event in cervical intraepithelial neoplasia. Diagn Mol Pathol 2006;15:74-82.
12. Kalof AN, Cooper K. p16INK4a immunoexpression: surrogate marker of high-risk HPV and high-grade cervical intraepithelial neoplasia. Adv Anat Pathol 2006;13:190-4.
13. INK4a as an indicator for human papillomavirus oncogenic activity in cervical squamous neoplasia. Int J Gynecol Cancer 2006;16:347-53.
14. Kong CS, Balzer BL, Troxell ML, Patterson BK, Longacre TA. p16INK4A immunohistochemistry is superior to HPV in situ hybridization for the detection of high-risk HPV in atypical squamous metaplasia. Am J Surg Pathol 2007;31:33-43.
15. Yildiz IZ, Usubütün A, Firat P, Ayhan A, Küçü kali T. Efficiency of immunohistochemical p16 expression and HPV typing in cervical squamous intraepithelial lesion grading and review of the p16 literature. Pathol Res Pract 2007;203: 445-9.
16. (INK4A) in normal uterine cervix, nonneoplastic epithelial lesions, and low-grade squamous intraepithelial lesions. J Low Genit Tract Dis 2007;11:98-104.
17. (INK4a) is predictive of HR-HPV infection in cervical low-grade lesions. Mod Pathol 2006;19:384-91.
18. Kalof AN, Evans M F, Simmons-Arnold L, Beatty BG, Cooper K. p16INK4A immunoexpression and HPV in situ hybridization signal patterns: potential markers of high-grade cervical intraepithelial neoplasia. Am J Surg Pathol 2005;29:674-9.
19. Lorenzato M, Caudroy S, Bronner C, Evrard G, Simon M, Durlach A, et al. Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions. Hum Pathol 2005;36:1101-7.
20. INK4a expression in cervical intraepithelial neoplasia of adolescents. Mod Pathol 2005;18:267-73.
21. INK4A, p14ARF, p53, and proliferating cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res 2004;10:2407-14.
22. INK4A positivity in benign, premalignant and malignant cervical glandular lesions: a potential diagnostic problem. Virchows Arch 2004;445:610-5.
23. (INK4A) expression is related to grade of cin and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 2004;23:354-65.
24. Agoff SN, Lin P, Morihara J, Mao C, Kiviat NB, Koutsky LA. p16(INK4a) expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 2003;16:665-73.
25. Klaes R, Benner A, Friedrich T, Ridder R, Herrington S, Jenkins D, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial neoplasia. Am J Surg Pathol 2002;26:1389-99.
26. Keating JT, Ince T, Crum C P. Surrogate biomarkers of HPV infection in cervical neoplasia screening and diagnosis. Adv Anat Pathol 2001;8:83-92.
27. (INK4a) and hybrid capture 2 human papillomavirus testing for high-grade cervical intraepithelial neoplasia. Am J Clin Pathol 2004;122:894-901.
28. Lambert A P, Anschau F, Schmitt VM. p16INK4A expression in cervical premalignant and malignant lesions. Exp Mol Pathol 2006;80:192-6.
29. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006;208:152-64.
30. Volgareva G, Zavalishina L, Andreeva Y, Frank G, Krutikova E, Golovina D, et al. Protein p16 as a marker of dysplastic and neoplastic alterations in cervical epithelial cells. BMC Cancer 2004;4:58.
31. Tripathi A, Banerjee S, Roy A, Roychowdhury S, Panda CK. Alterations of the P16 gene in uterine cervical carcinoma from Indian patients. Int J Gynecol Cancer 2003;13:472-9.
32. INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows Arch 2004;445:616-20.
33. Guimarães MC, Gonçalves MA, Soares C P, Bettini JS, Duarte RA, Soares EG. Immunohistochemical expression of p16INK4a and bcl-2 according to HPV type and to the progression of cervical squamous intraepithelial lesions. J Histochem Cytochem 2005;53:509-16.
34. von Knebel Doeberitz M. Aspects of molecular pathogenesis of cervical cancer in establishing new tumor markers for early detection and diagnosis. Zentralbl Gynakol 2001;123:186-91.
35. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998;153:1741-8.